REFERENCES
- Warrell RP, de The H, Wang Z, Degos L. Acute promyelocytic leukemia. N Englf Med. 1993;329:177–189.
- Watanabe R, Murata M, Takayama N, et al. Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans-retinoic acid for acute promyelocytic leukemia. Thromb Haemost. 1997;77:641–645.
- Hashimoto S, Koike T, Tatewaki W, et al. Fatal thromboembolism in acute promyelocytic leukemia during all-trans-retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hem-orrhage. Leukemia. 1994;8:1113.
- Mahendra P, Keeling DM, Hood IM, Baglin TP, Marcus RE. Fatal thromboembolism in acute promye-locytic leukaemia treate d with a combination of all-trans-retinoic acid and aprotinin. Clin Lab Haematol. 1996;18:51–52.
- Rodeghiero F, Awisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treat-ments in acute promyelocytic leukemia: a GIMEMA retrospective study in 268 consecutive patients. Blood. 1990;75: 2112–2117.
- Avvisati G, ten Cate JW, Bailer HR, Mandelli F. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet. 1989july 15:122–124.
- Schwartz BS, Williams EC, Conlan MG, Mosher DF. Epsilon-aminocaproic acid in the treatment of patients with acute promyelocytic leukemia and acquired alpha-2-plasmin inhibitor deficiency. Ann Intern Med. 1986;105:873–877.
- Nowak-Goal U, Binder M, Dabbers A, et al. Arg5°6 to Gln mutation in the factor V gene causes poor fibrinolytic response in children after venous occlusion. Thromb Haemost. 1997;78: 1115–1118.
- Sweeney JD, Blair AJ, Dupuis MP, King TC, Moulton AL, Herbert C. Aprotinin, cardiac surgery, and factor V Leiden. Transfusion. 1997;37:1173–1178.
- Sifontes MT, Nuss R, Hunger SP, Wilimas J, Jacobson U. The factor V Leiden mutation in children with cancer and thrombosis. Br J Haematol 1997;96:484–489.